Q-omics provides the consensus-scored TTTY16 profile across patient tissues and cancer cell-line models. TTTY16 expression is associated with patient survival in 8 of 34 cancer types, with the highest sampling consensus in READ. Among the 18 cancer types available for tumor–normal comparison, TTTY16 is differentially expressed in 3, with the highest sampling consensus in LUAD. Additionally, TTTY16 RNA expression shows 5,744 significant pathway-activity associations, with the highest sampling consensus in PRAD. Together, these results highlight READ, LUAD, and PRAD as cancer lineages where TTTY16 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for TTTY16 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes TTTY16 survival associations across molecular data types. TTTY16 RNA expression shows survival associations in the most cancer types (8). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible TTTY16 RNA expression–survival associations across cancer types. High TTTY16 expression shows unfavorable associations in READ, PCPG, LIHC, LUSC and KIRC, but favorable associations in BLCA. The READ Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify READ as the clearest survival context for TTTY16 RNA expression.
This table summarizes TTTY16 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 3. The strongest signals are observed in LUAD for RNA.
This table ranks reproducible tumor–normal expression differences for TTTY16. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. TTTY16 shows lower tumor expression in LUAD and LUSC and higher tumor expression in THCA. The LUAD box plot shows higher TTTY16 RNA expression in normal versus tumor tissue (log2 FC = −1.893, t-test p < 0.001).
This table shows molecular features associated with TTTY16 in patient tissues and cancer cell lines. In patient samples, TTTY16 shows the broadest associations at the RNA and protein expression levels, with PRAD recurring as the lineage with the largest associated feature set.
